Bombesin-like peptides in human endocrine tumors: quantitation, biochemical characterization, and secretion.
Bombesin-like immunoreactivity (BLI) in 20 human endocrine tumors was studied using an antiserum directed toward the C-terminal region of bombesin. Additionally, plasma BLI was assayed in normal subjects and patients with known BLI-containing tumors. In 7 tumors (medullary carcinoma of the thyroid, n = 2; carcinoid of the lung, n = 3; hepatic carcinoid, n = 1; pheochromocytoma, n = 1), the BLI content ranged from 6-2000 pg/mg wet wt of tissue. Sephadex G-50 gel chromatography of tumor extracts under acid-dissociating conditions revealed 2 peaks of BLI: 1 coeluting with porcine gastrin-releasing peptide (GRP) and 1 with bombesin. Reverse phase ODS silica HPLC analysis of the G-50 peaks using a methanol-trifluoroacetic acid gradient showed that human tumor BLI more closely resembled porcine GRP and its C-terminal fragment GRP-(14-27) than bombesin itself. Partial tryptic digestion of the tumor GRP-like peptide generated a product which, on HPLC, was similar to GRP-(14-27). Elevated plasma BLI was detected in the peripheral circulation of three subjects and in the vessels draining the tumor metastases of one of these patients. BLI was undetectable in normal subjects. These results indicate 1) that BLI is present in and may be secreted by various human endocrine tumors, and 2) that human tumor BLI closely resembles porcine GRP and its C-terminal fragment GRP-(14-27).
D000818:Animals; D002850:Chromatography, Gel; D002851:Chromatography, High Pressure Liquid; D019886:Gastrin-Releasing Peptide; D006801:Humans; D007106:Immune Sera / Q000032:analysis; D009369:Neoplasms / Q000097:blood / Q000378:metabolism*; D010446:Peptide Fragments / Q000032:analysis; D010455:Peptides / Q000097:blood / Q000276:immunology* / Q000378:metabolism; D013045:Species Specificity; D013552:Swine
D007106:Immune Sera; D010446:Peptide Fragments; D010455:Peptides; D019886:Gastrin-Releasing Peptide